Loading...
Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer
Median survival for patients with metastatic pancreatic cancer (MPC) treated with combination chemotherapeutic agents such as gemcitabine-based regimens and FOLFIRINOX is currently less than 12 months. This highlights the need for more efficacious first-line, as well as second-line therapies. Nanoli...
Saved in:
| Published in: | Therap Adv Gastroenterol |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
SAGE Publications
2017
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5484436/ https://ncbi.nlm.nih.gov/pubmed/28804517 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756283X17705328 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|